Vor Biopharma Inc. (VOR) stock
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 5/30
$17.83−0.35 (-1.93%)
Close on Nov 18, 2026Market cap $1.10BP/E –Yield –
Vor Biopharma cash
Cash and short-term investments held at the end of each period.
Vor Biopharma's cash was $481.60M at Sep 30, 2026. For fiscal 2025 it was $455.20M, up 395.3% from the year before. The highest annual figure on record is $455.20M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $455.20M | +395.3% |
| FY2024 | Dec 31, 2024 | $91.90M | -33.0% |
| FY2023 | Dec 31, 2023 | $137.18M | -40.4% |
| FY2022 | Dec 31, 2022 | $230.25M | +11.0% |
| FY2021 | Dec 31, 2021 | $207.47M | +327.4% |
| FY2020 | Dec 31, 2020 | $48.54M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $481.60M | +182.5% |
| Q2 FY2026 | Jun 30, 2026 | $466.10M | +132.4% |
| Q1 FY2026 | Mar 31, 2026 | $491.50M | +719.2% |
| Q4 FY2025 | Dec 31, 2025 | $455.20M | +395.3% |
| Q3 FY2025 | Sep 30, 2025 | $170.50M | +171.5% |
| Q2 FY2025 | Jun 30, 2025 | $200.60M | +133.5% |
| Q1 FY2025 | Mar 31, 2025 | $60.00M | -44.2% |
| Q4 FY2024 | Dec 31, 2024 | $91.90M | -33.0% |
| Q3 FY2024 | Sep 30, 2024 | $62.80M | -60.8% |
| Q2 FY2024 | Jun 30, 2024 | $85.90M | -54.0% |
| Q1 FY2024 | Mar 31, 2024 | $107.48M | -48.9% |
| Q4 FY2023 | Dec 31, 2023 | $137.18M | -40.4% |
| Q3 FY2023 | Sep 30, 2023 | $160.10M | +17.7% |
| Q2 FY2023 | Jun 30, 2023 | $186.90M | +23.7% |
| Q1 FY2023 | Mar 31, 2023 | $210.20M | +15.7% |
| Q4 FY2022 | Dec 31, 2022 | $230.25M | +11.0% |
| Q3 FY2022 | Sep 30, 2022 | $136.07M | -39.8% |
| Q2 FY2022 | Jun 30, 2022 | $151.09M | -38.2% |
| Q1 FY2022 | Mar 31, 2022 | $181.62M | -30.8% |
| Q4 FY2021 | Dec 31, 2021 | $207.47M | +327.4% |
| Q3 FY2021 | Sep 30, 2021 | $225.97M | +255.3% |
| Q2 FY2021 | Jun 30, 2021 | $244.63M | +235.5% |
| Q1 FY2021 | Mar 31, 2021 | $262.57M | – |
| Q4 FY2020 | Dec 31, 2020 | $48.54M | – |
| Q3 FY2020 | Sep 30, 2020 | $63.60M | – |
| Q2 FY2020 | Jun 30, 2020 | $72.91M | – |
See a number that looks wrong?